U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07306299) titled 'A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma' on Dec. 14.
Brief Summary: This clinical trial is designed to evaluate the safety and efficacy of a universal mRNA vaccine targeting a panel of glioma-associated mutations in patients with recurrent or progressive high-grade glioma.
The primary objectives are to address the following key questions: 1) Is the mRNA vaccine safe for this patient population? 2) Does the vaccine stimulate an anti-tumor immune response and promote tumor regression?
Participants will receive the vaccine according to the following schedule:
1. one injection per wee...